Cerdulatinib

Cerdulatinib
Clinical data
Other names	PRT062070, PRT2070, DMVT-502
Routes of; administration	By mouth
Identifiers
	IUPAC name 4-(Cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide;
CAS Number	1198300-79-6 [PubChem];
PubChem CID	44595079;
ChemSpider	32822046 ;
UNII	D1LXQ45S1O;
CompTox Dashboard (EPA)	DTXSID001115521 ;
Chemical and physical data
Formula	C20H27N7O3S
Molar mass	445.54 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C(C(=N3)NC4CC4)C(=O)N;
	InChI InChI=1S/C20H27N7O3S/c1-2-31(29,30)27-11-9-26(10-12-27)16-7-5-15(6-8-16)24-20-22-13-17(18(21)28)19(25-20)23-14-3-4-14/h5-8,13-14H,2-4,9-12H2,1H3,(H2,21,28)(H2,22,23,24,25) ; Key:BGLPECHZZQDNCD-UHFFFAOYSA-N;

Cerdulatinib is a small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies.^[1] It has lowest nM IC50 values against TYK2, JAK1, JAK2, JAK3, FMS, and SYK.^[2]

It is being developed by Portola Pharmaceuticals; in September 2018 the FDA granted orphan drug status to cerdulatinib for the treatment of peripheral T-cell lymphoma (PTCL).^[3]

References

^ Liu D, Mamorska-Dyga A (July 2017). "Syk inhibitors in clinical development for hematological malignancies". Journal of Hematology & Oncology. 10 (1): 145. doi:10.1186/s13045-017-0512-1. PMC 5534090. PMID 28754125.{{cite journal}}: CS1 maint: unflagged free DOI (link)
^ Coffey G, Betz A, DeGuzman F, Pak Y, Inagaki M, Baker DC, et al. (December 2014). "The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer". The Journal of Pharmacology and Experimental Therapeutics. 351 (3): 538–48. doi:10.1124/jpet.114.218164. PMID 25253883.
^ "Investors - News Release - Portola Pharmaceuticals, Inc". phx.corporate-ir.net. September 25, 2018.